Table 2.
Clinical trials of Sunitinib in patients with thyroid cancer.
| Drug | Thyroid Cancer | Responses | Authors | |||
|---|---|---|---|---|---|---|
| PR | SD | PD | PFS (months) | |||
| Sunitinib | 37 DeTC 6 MTC |
13% DeTC | 68% DeTC 83% MTC |
10% DeTC 17% MTC |
Cohen et al. [74] | |
| Sunitinib | 12 DeTC 1 ATC 4 MTC |
6% | 71% | Ravaud et al. [76] | ||
| Sunitinib | 7 MTC 28 DeTC |
28% PR + 3% CR | 46% | 17% | 12.8 | Carr et al. [77] |
| Sunitinib | 11 DeTC | 18% PR + 9% CR | 45% | 27% | 11.5 | Dìez et al. [78] |
Anaplastic thyroid cancer (ATC); complete response (CR); dedifferentiated thyroid cancer (DeTC); medullary thyroid cancer (MTC); partial response (PR); progressive disease (PD); progression-free survival (PFS); stable disease (SD).